These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 35937997)
1. Identification of Crucial Gene Modules Related to the Efficiency of Anti-PD-1/PD-L1 Therapy and Comprehensive Analyses of a Novel Signature Based on These Modules. Wang W; Dong D; Chen L; Wang H; Bi B; Liu T Front Genet; 2022; 13():893380. PubMed ID: 35937997 [TBL] [Abstract][Full Text] [Related]
2. Conserved immuno-collagenic subtypes predict response to immune checkpoint blockade. Mei J; Cai Y; Xu R; Li Q; Chu J; Luo Z; Sun Y; Shi Y; Xu J; Li D; Liang S; Jiang Y; Liu J; Qian Z; Zhou J; Wan M; Yang Y; Zhu Y; Zhang Y; Yin Y Cancer Commun (Lond); 2024 May; 44(5):554-575. PubMed ID: 38507505 [TBL] [Abstract][Full Text] [Related]
3. A bioinformatics-based immune-related prognostic index for lung adenocarcinoma that predicts patient response to immunotherapy and common treatments. Wang C; Lu T; Xu R; Chang X; Luo S; Peng B; Wang J; Yao L; Wang K; Shen Z; Zhao J; Zhang L J Thorac Dis; 2022 Jun; 14(6):2131-2146. PubMed ID: 35813746 [TBL] [Abstract][Full Text] [Related]
4. Immune subtyping for pancreatic cancer with implication in clinical outcomes and improving immunotherapy. Liu J; Liu Q; Zhang X; Cui M; Li T; Zhang Y; Liao Q Cancer Cell Int; 2021 Feb; 21(1):137. PubMed ID: 33637086 [TBL] [Abstract][Full Text] [Related]
5. Tumor Microenvironment Heterogeneity-Based Score System Predicts Clinical Prognosis and Response to Immune Checkpoint Blockade in Multiple Colorectal Cancer Cohorts. Wang H; Li Z; Ou S; Song Y; Luo K; Guan Z; Zhao L; Huang R; Yu S Front Mol Biosci; 2022; 9():884839. PubMed ID: 35836930 [TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma. Fröhlich A; Loick S; Bawden EG; Fietz S; Dietrich J; Diekmann E; Saavedra G; Fröhlich H; Niebel D; Sirokay J; Zarbl R; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D EBioMedicine; 2020 Feb; 52():102647. PubMed ID: 32028068 [TBL] [Abstract][Full Text] [Related]
7. A Comprehensive Proteogenomic and Spatial Analysis of Innate and Acquired Resistance of Metastatic Melanoma to Immune Checkpoint Blockade Therapies. Wei S; Du K; Lan H; Yang Z; Deng Y; Wei Z; Frederick DT; Lee J; Labrie M; Tian T; Moll T; Chen Y; Sullivan RJ; Mills G; Boland GM; Flaherty KT; Liu L; Herlyn M; Zhang G bioRxiv; 2024 Sep; ():. PubMed ID: 39314469 [TBL] [Abstract][Full Text] [Related]
8. Clustering by antigen-presenting genes reveals immune landscapes and predicts response to checkpoint immunotherapy. Gong X; Karchin R Sci Rep; 2023 Jan; 13(1):950. PubMed ID: 36653470 [TBL] [Abstract][Full Text] [Related]
9. Circadian pattern subtyping unveiling distinct immune landscapes in breast cancer patients for better immunotherapy. Xiong S; Zhu W; Wu L; Zhou T; Wang W; Zhang O; Xiong X; Liu Z; Luo D Cancer Immunol Immunother; 2023 Oct; 72(10):3293-3307. PubMed ID: 37462763 [TBL] [Abstract][Full Text] [Related]
10. MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma. de Azevedo RA; Shoshan E; Whang S; Markel G; Jaiswal AR; Liu A; Curran MA; Travassos LR; Bar-Eli M Oncoimmunology; 2020 Dec; 9(1):1846915. PubMed ID: 33344042 [TBL] [Abstract][Full Text] [Related]
11. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer. Lal JC; Townsend MG; Mehta AK; Oliwa M; Miller E; Sotayo A; Cheney E; Mittendorf EA; Letai A; Guerriero JL Breast Cancer Res; 2021 Aug; 23(1):83. PubMed ID: 34353349 [TBL] [Abstract][Full Text] [Related]
12. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer. Isaacs J; Anders C; McArthur H; Force J Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085 [TBL] [Abstract][Full Text] [Related]
13. A Predictive Network-Based Immune Checkpoint Blockade Immunotherapeutic Signature Optimizing Patient Selection and Treatment Strategies. Zhang N; Yang M; Yang JM; Zhang CY; Guo AY Small Methods; 2024 Oct; 8(10):e2301685. PubMed ID: 38546036 [TBL] [Abstract][Full Text] [Related]
14. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3. Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262 [TBL] [Abstract][Full Text] [Related]
15. Development of a T-cell activation-related module with predictive value for the prognosis and immune checkpoint blockade therapy response in glioblastoma. Yan Z; Chu S; Zhu C; Han Y; Liang Q; Shen S; Cheng W; Wu A PeerJ; 2021; 9():e12547. PubMed ID: 35036121 [TBL] [Abstract][Full Text] [Related]
16. A Cancer Associated Fibroblasts-Related Six-Gene Panel for Anti-PD-1 Therapy in Melanoma Driven by Weighted Correlation Network Analysis and Supervised Machine Learning. Tian L; Long F; Hao Y; Li B; Li Y; Tang Y; Li J; Zhao Q; Chen J; Liu M Front Med (Lausanne); 2022; 9():880326. PubMed ID: 35479936 [TBL] [Abstract][Full Text] [Related]
17. A 12-chemokine gene signature is associated with the enhanced immunogram scores and is relevant for precision immunotherapy. Li X; Wan Z; Liu X; Ou K; Yang L Med Oncol; 2022 Jan; 39(4):43. PubMed ID: 35092511 [TBL] [Abstract][Full Text] [Related]
18. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553 [TBL] [Abstract][Full Text] [Related]
19. Deactivation of ligand-receptor interactions enhancing lymphocyte infiltration drives melanoma resistance to Immune Checkpoint Blockade. Sahni S; Wang B; Wu D; Dhruba SR; Nagy M; Patkar S; Ferreira I; Wang K; Ruppin E bioRxiv; 2023 Sep; ():. PubMed ID: 37886558 [TBL] [Abstract][Full Text] [Related]
20. The Landscape of the Tumor Microenvironment in Skin Cutaneous Melanoma Reveals a Prognostic and Immunotherapeutically Relevant Gene Signature. Zhou S; Sun Y; Chen T; Wang J; He J; Lyu J; Shen Y; Chen X; Yang R Front Cell Dev Biol; 2021; 9():739594. PubMed ID: 34660598 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]